Overview

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Molecular Insight Pharmaceuticals, Inc.

Treatments:

3-Iodobenzylguanidine